Table 4.

Baseline factors associated with sustained virologic response

	SVR			Unadjusted			Adjusted*
Variable	N=352	n=193	%	OR	95% CI	p-value	OR	95% CI	p-value
Protease inhibitor
Telaprevir	211	118	56%	1.0			1.0
Boceprevir	141	75	53%	0.9	(0.58 – 1.37)	0.61	0.82	(0.52 – 1.28)	0.38
Cirrhosis
No	279	166	59%	1.0			1.0
Yes	73	27	37%	0.4	(0.23 – 0.68)	0.001	0.44	(0.25 – 0.77)	0.004
Sex
Male	213	120	56%	1.0			1.0
Female	139	73	53%	0.86	(0.56 – 1.32)	0.48	0.77	(0.49 – 1.21)	0.26
Race
Non-Black	300	169	56%	1.0			1.0
Black	52	24	46%	0.66	(0.37 – 1.20)	0.18	0.61	(0.33 – 1.14)	0.12
Prior treatment
Naïve, relapsers	239	145	61%	1.0			1.0
Other previously treated	113	48	42%	0.48	(0.30 – 0.75)	0.002	0.57	(0.35 – 0.91)	0.02
HCV RNA
<800,000 IU/mL	152	89	59%	1.0			1.0
≥800,000 IU/mL	200	104	52%	0.77	(0.50 – 1.17)	0.22	0.78	(0.50 – 1.21)	0.27
HCV subtype
1b	111	63	57%	1.0
1a and other	241	130	54%	0.89	(0.57 – 1.40)	0.62
Age
<60 years	244	135	55%	1.0
≥60 years	108	58	54%	0.94	(0.59 – 1.48)	0.78
BMI
Non-obese (<30 kg/m2)	225	128	57%	1.0
Obese (≥ 30 kg/m2)	127	65	51%	0.79	(0.51 – 1.23)	0.30
Platelet count (×109/L)
≥150	242	132	55%	1.0
<150	110	61	55%	1.04	(0.66 – 1.63)	0.87
Diabetes
No	294	163	55%	1.0
Yes	58	30	52%	0.86	(0.49 – 1.51)	0.60

SVR: sustained virologic response; BMI: body mass index.

^*Model includes protease inhibitor, cirrhosis, sex, race, prior treatment, and HCV RNA.